370 related articles for article (PubMed ID: 29066057)
21. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
22. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer.
Qi S; Mao Y; Jiang M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1115-1123. PubMed ID: 31502113
[TBL] [Abstract][Full Text] [Related]
23. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
24. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
27. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
Chen YH; Lu HI; Chien CY; Lo CM; Wang YM; Chou SY; Su YY; Shih LH; Li SH
Sci Rep; 2017 Jan; 7():41785. PubMed ID: 28134308
[TBL] [Abstract][Full Text] [Related]
28. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
29. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
[TBL] [Abstract][Full Text] [Related]
30. Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer.
Shinoto M; Shioyama Y; Sasaki T; Nakamura K; Ohura H; Toh Y; Higaki Y; Yamaguchi T; Ohnishi K; Atsumi K; Hirata H; Honda H
Am J Clin Oncol; 2011 Aug; 34(4):362-6. PubMed ID: 20686402
[TBL] [Abstract][Full Text] [Related]
31. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
33. [Concurrent chemoradiotherapy with nedaplatin and 5-fluorouracil (5-fu) for locally advanced squamous cell carcinoma of the esophagus].
Kubo N; Morimoto J; Tanaka H; Ohira M; Noda E; Amano R; Inoue T; Yamada N; Yashiro M; Maeda K; Yamashita Y; Muguruma K; Sawada T; Hirakawa K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1997-9. PubMed ID: 20037303
[TBL] [Abstract][Full Text] [Related]
34. A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis.
Deng W; Wang Q; Xiao Z; Tan L; Yang Z; Zhou Z; Zhang H; Chen D; Feng Q; Liang J; Li Y; He J; Gao S; Sun K; Cheng G; Liu X; Fang D; Xue Q; Mao Y; Wang D; Li J
Oncotarget; 2017 Jun; 8(25):41102-41112. PubMed ID: 28456788
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
[TBL] [Abstract][Full Text] [Related]
36. Esophageal adenocarcinoma stage III: Survival based on pathological response to neoadjuvant treatment.
Schwameis K; Zehetner J; Hagen JA; Oh DS; Worrell SG; Rona K; Cheng N; Samaan J; Green KM; Lipham JC
Surg Oncol; 2017 Dec; 26(4):522-526. PubMed ID: 29113673
[TBL] [Abstract][Full Text] [Related]
37. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.
Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J
Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597
[TBL] [Abstract][Full Text] [Related]
38. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
40. [A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis].
YANG H; FU JH; LIU MZ; FANG WT; WANG JM; CHEN YP; CHEN ZJ; XIANG JQ; YANG HJ; MAO WM; ZHENG X; ZHU CC; KONG M; HAN YT; LI T
Zhonghua Yi Xue Za Zhi; 2012 Apr; 92(15):1028-32. PubMed ID: 22781642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]